STE at a glance
Steris (STE, SEC CIK 1757898) filed its latest 10-K annual report on May 29, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 31, 2026 (FY2026), Steris (STE) reported revenue of $5.9 billion (up 8.7% from FY2025) and net income of $782.3 million. Diluted EPS was $7.93.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Steris (STE) shares worth $9.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Madsen Julia on November 13, 2026 of 2,046 shares at $260.00 per share.
- In the last 90 days, STE insiders reported 0 open-market purchases ($0) and 4 open-market sales ($3.3M) on Form 4, a net sale of $3.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $5.9B
- +8.7% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$3.3M
- 13F holders
- 38 funds
- $9.0B · −3 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q2 revenue $1,588.6M, up 8.8% YoY from $1,460.3M
- Gross margin 44.7% vs 44.2% YoY; operating income $294.3M vs $265.8M
- Best segment Life Sciences: revenue $170.6M, up 17.7%; margin 44.4% vs 41.3%
- Healthcare weakest margin trend: 24.0% vs 25.1%, despite revenue growth of 8.6% to $1,122.4M
- Six-month operating cash flow $656.1M vs $707.8M; free cash flow $492.5M vs $527.7M, with $200.0M share repurchases
Risk Factors
- New transaction risk: Xodus Medical Acquisition could fail to close, with termination permitted after July 12, 2027
- Regulatory risk: Hart-Scott-Rodino approval and other antitrust clearances could require divestitures or remedies
- Operational risk: Acquisition uncertainty could cause employee departures and customer, supplier, or partner disruptions
- Financial risk: Approximately $2.0 billion additional debt expected, versus $1.9 billion outstanding at September 30, 2026
- Financing risk: Bridge facility may carry higher costs and shorter maturities if permanent financing terms prove unacceptable
AI summary of the STE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- $1.5B senior-note offering, split between $750M due 2033 and $750M due 2036
- Fixed interest rates of 5.650% and 5.875%, respectively, increasing recurring interest expense
Item 2.02: Results of Operations and Financial Condition
- STERIS announced fiscal second-quarter 2026 results for the quarter ended September 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Fiscal Q2 revenue $1.6B, up 9%, with 8.1% constant-currency organic growth, indicating broad underlying demand
- Adjusted diluted EPS $2.94, up from $2.47, while GAAP EPS reached $2.19 from $1.94
Item 1.01: Entry into a Material Definitive Agreement
- New $1.6B revolving facility replaces existing agreement, with maturity extended to November 4, 2031
- Revolver supports liquidity, letters of credit and swingline borrowings, with potential $800M commitment expansion
Item 1.02: Termination of a Material Definitive Agreement
- Existing Revolving Credit Agreement termination disclosed through Item 1.01 cross-reference
- Investors should review Item 1.01 for replacement financing terms and potential liquidity implications
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 links to Item 1.01, indicating a material agreement created a direct financial obligation
- Investors should review Item 1.01 for the obligation’s amount, terms, maturity and business purpose
AI summaries of STE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for STE
Don't miss the next STE filing
- Alerts as it files. A push when STE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut STE, by share count.
- Ask anything. An AI agent that reads every STE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Madsen Julia | Sell | Nov 13, 2026 | 2,046 | $260.00 |
| Burton Karen L | M | Nov 11, 2026 | 5,880 | - |
| Burton Karen L | Sell | Nov 11, 2026 | 5,880 | $255.62 |
| Burton Karen L | M | Nov 11, 2026 | 5,880 | $147.05 |
| Sohi Mohsen | Sell | Nov 10, 2026 | 3,228 | $252.87 |
| Sohi Mohsen | M | Nov 10, 2026 | 4,893 | $114.74 |
| Sohi Mohsen | Sell | Nov 10, 2026 | 1,665 | $253.90 |
| Sohi Mohsen | M | Nov 10, 2026 | 4,893 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $5.5B | $5.9B |
| Gross Profit | - | $2.4B | $2.6B |
| Operating Income | - | $866.6M | $1.1B |
| Net Income | - | $614.6M | $782.3M |
| Gross Margin | - | 44.0% | 44.2% |
| Op. Margin | - | 15.9% | 18.6% |
| Net Margin | - | 11.3% | 13.2% |
| Balance Sheet | |||
| Total Assets | $11.1B | $10.1B | $10.7B |
| Equity | $6.3B | $6.6B | $7.2B |
| ROE | - | 9.3% | 10.9% |
| Per Share | |||
| EPS | - | $6.20 | $7.93 |
| Cash Flow | |||
| Operating CF | - | $1.1B | $1.3B |
| CapEx | - | $370.1M | $369.0M |
Source: XBRL data in Steris (STE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate STE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $9.05B |
| Q2 2026 | 41 | $9.09B |
| Q1 2026 | 37 | $9.54B |
| Q4 2025 | 35 | $10.48B |
| Q3 2025 | 37 | $10.39B |
| Q2 2025 | 34 | $9.63B |
| Q1 2025 | 33 | $6.85B |
| Q4 2024 | 30 | $4.98B |
- BlackRock+1.00M (+11%)
- AQR Capital Management+691.2K (+50%)
- State Street Corp+108.1K (+2%)
- Citigroup+76.4K (+35%)
- T. Rowe Price Group+61.3K (+3%)
- Goldman Sachs Group−920.3K (-68%)
- Morgan Stanley−302.9K (-8%)
- D.E. Shaw & Co−186.8K (-37%)
- Citadel Advisors LLC−182.2K (-45%)
- Raymond James Financial−168.2K (-28%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 285 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
STE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 12, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
STE SEC filings: frequently asked questions
Are STE insiders buying or selling?
In the last 90 days, Steris (STE) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $3.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold STE stock?
As of September 30, 2026, the largest Steris (STE) holders among the 13F filers tracked by SignalX were BlackRock ($2.1 billion), Vanguard Capital Management LLC ($1.3 billion), State Street Corp ($1.1 billion), Vanguard Portfolio Management LLC ($1.0 billion), Morgan Stanley ($765.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was STE's revenue in fiscal year 2026?
For the fiscal year ended March 31, 2026 (FY2026), Steris (STE) reported revenue of $5.9 billion (up 8.7% from FY2025) and net income of $782.3 million. Diluted EPS was $7.93. The figures come from the XBRL data in the 10-K.
What did STE report in its latest 8-K?
Steris (STE) filed an 8-K on November 12, 2026 reporting Item 8.01 (Other Events). $1.5B senior-note offering, split between $750M due 2033 and $750M due 2036.
What are the latest STE SEC filings?
Steris (STE) filed its latest 10-K annual report on May 29, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 17, 2026.
What is STE's SEC CIK number?
Steris (STE)'s SEC Central Index Key (CIK) is 1757898. EDGAR lists every STE filing under that number.
Ask anything about STE
The research agent reads STE's filings, financials, insider trades and 13F holders, then answers with sources.